Fibrocell Science Reports Fourth Quarter and Full Year 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating Results

- Significant progress advancing gene therapy candidate for recessive dystrophic epidermolysis bullosa ( RDEB), a devastating and progressive orphan skin disease -

- Phase II clinical trial progressing for vocal cord scarring -

- Company to Host Conference Call and Webcast, Today at 8:30 a.m. EDT -

EXTON, Pa., March 13, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC ), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the fourth quarter and fiscal year ended December 31, 2014. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.

"We have made great progress advancing our pipeline and we are continuing this momentum going forward," said David Pernock, Chairman and Chief Executive Officer of Fibrocell. "In collaboration with Intrexon Corporation (NYSE: XON ), a leader in synthetic biology, we expect to submit an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) in mid-2015 for our recessive dystrophic epidermolysis bullosa (RDEB) gene therapy candidate, GM-HDF-COL7 (genetically-modified human dermal fibroblast, collagen VII). We will also continue to advance development of our gene therapy program for linear scleroderma, a chronic, debilitating autoimmune disease."

"Our most advanced clinical program in Phase II for vocal cord scarring is progressing. Our goal is to complete this Phase II trial with data from 20 patients. Toward that end, we have currently enrolled 22 patients and will continue to recruit to allow for any potential discontinuations that may occur during the course of the trial. Patients suffering from this serious condition experience significantly distorted voices or even complete loss of voice, dramatically impacting their ability to communicate. Our treatment approach could have a significant impact in helping to restore these patients' voices."

Fourth Quarter 2014 and Early 2015 Highlights

  • Fibrocell was notified by the Recombinant DNA Advisory Committee (RAC), a subsidiary of the National Institutes of Health governing gene therapy, that the review was completed of Fibrocell's submission for GM-HDF-COL7, Fibrocell's RDEB gene therapy product candidate. Based on that review, Fibrocell is not required to appear before the RAC committee as its submission did not raise any issues warranting further review. Fibrocell remains on track to file an IND application with the FDA and initiate clinical testing later this year.
     
  • Fibrocell received an IND application allowance from the FDA permitting Fibrocell to proceed with development of a cell therapy treatment for amputee stump skin to prevent prosthesis abandonment. Fibrocell plans to proceed with a clinical study pending award of a grant from the U.S. Department of Defense.

Financial Results

Quarter ended December 31, 2014 compared to quarter ended December 31, 2013

For the quarterly period ended December 31, 2014, Fibrocell reported a basic net loss of $0.08 per share, compared to a basic net loss of $0.15 per share for the same period in 2013. Revenues for each of the fourth quarters of 2014 and 2013 were insignificant. Fibrocell used $6.8 million in cash for operations during the fourth quarter of 2014, as compared to $4.0 million in the fourth quarter of 2013.

Operating loss was $6.2 million for the quarter ended December 31, 2014 as compared to $5.7 million for the same period in 2013. The increase of $0.5 million was due primarily to increases in selling, general and administrative expenses and research and development expenses of $0.3 million and $1.2 million, respectively, offset by a decrease in cost of sales of $0.9 million.

Selling, general and administrative expenses for the quarter ended December 31, 2014 were $2.5 million, as compared to $2.2 million for the same period in 2013. The $0.3 million increase was due primarily to an increase of $0.5 million in facilities and related expense and other due to increases in repairs and maintenance costs and office and other general expenses and an increase in severance costs in the fourth quarter of 2014 of $0.2 million, offset by decreases of $0.3 million in professional fees and $0.1 million in compensation.

Research and development expenses for the quarterly period ended December 31, 2014 were $3.3 million, as compared to $2.1 million for the same period in 2013. The $1.2 million increase was due primarily to an increase of $0.7 million in indirect lab costs due to the 2014 implementation of a standard cost system which resulted in the allocation of manufacturing and quality costs not related to commercial sales to research and development expense, a $0.3 million increase in costs associated with our RDEB preclinical program, and a $0.2 million increase in costs associated with our Phase II clinical trial for vocal cord scarring.

Twelve months ended December 31, 2014 compared to twelve months ended December 31, 2013

For the twelve months ended December 31, 2014, Fibrocell reported a basic net loss of $0.63 per share, compared to a basic net loss of $1.06 per share for the same period in 2013. Revenues for the twelve months of 2014 and 2013 were insignificant. Fibrocell used $22.3 million in cash for operations during 2014, as compared to $20.1 million for the comparable period in 2013.

Operating loss was $30.0 million for the twelve months of 2014 compared to $30.5 million for the same period in 2013. The decrease of $0.5 million was due to primarily to a decrease in cost of sales of $5.2 million, and offset by increases in selling, general and administrative expenses and research and development expenses of $2.2 million and $2.4 million, respectively.

Selling, general and administrative expenses were $11.6 million, an increase of $2.2 million compared to the twelve months ended December 30, 2013. Compensation and related expense increased approximately $0.9 million, due primarily to $0.5 million in employee bonuses, $0.2 million in severance costs, increased salaries of $0.1 million and increased stock compensation of $0.1 million. Professional fees increased approximately $0.7 million, primarily due to the $0.4 million in accounting and audit related costs for our warrant restatement project in the second quarter of fiscal 2014 and an increase of $0.3 million in temporary staffing costs. Legal fees increased approximately $0.4 million due to negotiations with respect to our corporate contracts as well as the warrant restatement project. Facilities and related expense and other increased approximately $0.4 million due to a $0.3 million increase in repairs and maintenance costs and a $0.1 million increase in office and other general expenses. These increases were offset by a decrease of marketing expense of $0.2 million due to the de-emphasis on sales of our commercial product, LAVIV®.

Research and development expenses for the twelve months ended December 31, 2014 were $16.2 million, as compared to $13.8 million for the same period in 2013. The $2.4 million increase primarily relate to an increase of $2.1 million in indirect lab costs and other expenses due to the 2014 implementation of a standard cost system which resulted in the allocation of manufacturing and quality costs not related to commercial sales to research and development expense, a $0.2 million increase in total direct costs and $0.1 million increase in other indirect costs.

Cash and cash equivalents totaled $37.5 million as of December 31, 2014 compared to $60.0 million on December 31, 2013. Cash was used primarily to fund core business initiatives.

Conference Call and Webcast

The conference call may be accessed by dialing 855-877-0343 for domestic callers and 678-509-8772 for international callers. Please specify to the operator that you would like to join the "Fibrocell Science Fourth Quarter and Full Year 2014 Financial Results Call, conference ID#: 84694384." The conference call will be webcast live under the investor relations section of  Fibrocell's website at www.fibrocellscience.com/investors/events-and-presentations/ , and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (Nasdaq: FCSC ) is an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Working in collaboration with Intrexon Corporation (NYSE: XON ), a leader in synthetic biology, Fibrocell is developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts as the delivery vehicle. Fibrocell's lead gene therapy, orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Fibrocell's second gene therapy program is focused on developing a treatment for linear scleroderma. Fibrocell is also pursuing medical applications for its proprietary autologous fibroblast technology, azficel-T. Currently, Fibrocell is in a Phase II clinical trial for vocal cord scarring. For additional information, visit www.fibrocellscience.com .

Forward-Looking Statements

This press release contains, and our officers and representatives may from time to time make, statements that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, among others, statements we make regarding our development strategy, timing and potential advantages of our product candidates.

These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell's control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) uncertainties relating to the initiation and completion of clinical trials; and (ii) whether clinical trial results will validate and support the safety and efficacy of our product candidates, as well as those set forth under the caption "Item 1A. Risk Factors" in Fibrocell's most recent Form 10-K filing.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell's most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell's most recent annual report.

Fibrocell Science, Inc.
Selected Financial Information
(unaudited)
Consolidated Statement of Operations:
         
  Three months
ended
December 31,
Three months
ended
December 31,
 
Year ended
December 31,
 
Year ended
December 31,
($ in thousands, except per share and share data) 2014 2013 2014 2013
         
Revenue from product sales $ 56 $ 44 $ 180 $ 200
Cost of sales 460 1,392 2,312 7,501
Gross loss (404) (1,348) (2,132) (7,301)
Selling, general and administrative expense 2,511 2,177 11,623 9,440
Research and development expense 3,252 2,126 16,199 13,762
Operating loss (6,167) (5,651) (29,954) (30,503)
Other income (expense):        
Warrant revaluation income (expense) 2,795 (93) 3,930 (1,053)
Other income (2) -- 368 --
Interest income 2 2 6 2
Loss before income taxes (3,372) (5,742) (25,650) (31,554)
Income tax expense -- -- -- --
Net loss $ (3,372) $ (5,742) $ (25,650) $  (31,554)
         
Per share information:        
         
Net loss per share        
Basic $ (0.08)  $ (0.15) $ (0.63) $ (1.06)
Diluted  $ (0.09) $ (0.15) $ (0.70) $ (1.12)
Weighted average number of basic   common shares outstanding 40,856,815 39,584,342 40,789,445 29,830,207
Weighted average number of diluted
 common shares outstanding
40,943,184 39,990,469 40,969,399 30,196,616
         
     
Fibrocell Science, Inc.
Selected Financial Information
(unaudited)
     
Selected Consolidated Balance Sheet Data:    
     
($ in thousands) December 31,
2014
December 31,
2013
     
Assets    
Current assets:    
Cash and cash equivalents $ 37,495 $ 60,033
Accounts receivable, net 4 28
Inventory 571 597
Prepaid expenses and other current assets 1,278 1,202
Total current assets 39,348 61,860
Property and equipment, net 1,598 1,701
Intangible assets, net 4,687 5,238
Other assets 1 215
Total assets $ 45,634 $ 69,014
     
Liabilities and Stockholder's Equity    
Total current liabilities $ 3,493 $ 3,593
Warrant liability, long term 11,008 15,216
Other long term liabilities 724 539
Total liabilities 15,225 19,348
Total stockholder's equity 30,409 49,666
Total liabilities and stockholder's equity $ 45,634 $ 69,014
     
Selected Consolidated Statement of Cash Flows Data:    
     
  Year ended December 31,
($ in thousands) 2014 2013
     
Net cash used in operating activities $ (22,296) $ (20,075)
Net cash used in investing activities $ (242) $ (360)
Net cash provided by financing activities $ -- $ 49,122

Investor Relations Contact: Karen Casey Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, PA 19341 (484) 713-6133

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 99

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 27

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

Director Declaration - Northern 2 VCT PLC

Updated Category News Views 143

Director Declaration - Northern 2 VCT PLC Northern 2 VCT PLC (“the Company”) has announced that Ranjan Ramparia, who currently serves as a non-executive director and audit Chair of the Company, will take on a new role as a non-executive director at Keystone Positive Change Investment Trust plc. Disclosure Compliance In line with the UK Listing Rules, there are no...

Continue Reading
Exploring WisdomTree's Diverse Fund Offerings and Prices

Updated Category News Views 119

Understanding WisdomTree's Daily Fund Prices WisdomTree Issuer plc, renowned for its innovative investment strategies, provides a range of ETF products that cater to various investment needs. The company focuses on not just traditional asset classes but also on megatrends shaping the future. Investors looking to stay updated on their financial assets can explore the daily...

Continue Reading
Atlantic American Corporation Sees Positive Growth in Q1 Results

Updated Category News Views 198

Atlantic American Corporation Achieves Strong Q1 Performance Atlantic American Corporation (NASDAQ: AAME) recently announced its financial results for the first quarter of the year, showcasing a significant turnaround in performance. The company reported a net income of $0.8 million, translating to $0.03 per diluted share. This marks a remarkable recovery from a net loss...

Continue Reading
CTT's Growth in Q3 2024: A Promising Outlook for Q4

Updated Category News Views 80

CTT's Impressive Q3 Performance CTT (CTT.LS) reported a stellar third quarter, showcasing significant revenue growth and a bright outlook for the fourth quarter. As discussed by CEO Joao Bento, the company achieved a remarkable 17.3% increase in revenue, accompanied by a 28.6% rise in EBIT when excluding Financial Services. This transition period highlights CTT's...

Continue Reading
Global Leaders Unite for Climate Justice Summit in NYC

Updated Category News Views 186

Global Leaders Come Together for Climate Justice Summit in NYC The Climate Justice Summit: People Deliver marks a significant kickoff for Climate Week in New York City. This vibrant event will gather a broad spectrum of climate justice advocates from around the world, who will collaborate and share their insights. A coalition of key organizations, including the HBCU Green...

Continue Reading